Abstract: A method for monitoring and controlling neutron beams includes performing a calibration process for a monitoring dosimeter at a first set of conditions for directing a neutron beam towards an object location, the neutron beam being emitted from a neutron-generating target in response to an incident charged particle beam, the process comprising: obtaining data indicating a first neutron flux measured by the monitoring dosimeter between the monitoring dosimeter and the object location, the monitoring dosimeter offset from the axis by a distance equal to or greater than the beam radius; obtaining data indicating a second neutron flux measured by a reference dosimeter between the target and the object location; storing calibration data including a correlation between the first neutron flux and the second neutron flux; and based on the calibration data, using the monitoring dosimeter to monitor neutron flux incident on a patient during boron neutron capture therapy treatment.

Abstract: Borylated Amino Acid compositions comprising tyrosine derivatives BTS and BTS(OMe) and novel methods of making BTS and BTS(OMe) are disclosed herein. Consequently, the BTS and/or BTS(OMe) can be scaled up to commercial scale and administered to patients as a Neutron Capture Agent and provide a method of treating cancer, immunological disorders, and other disease by utilizing a Neutron Capture Therapy modality.

Abstract: Antibodies that bind Her2, EGFR, Trop2, CDH3 or other TAAs containing a triple mutation at L234A, L235A, and L328C and methods of making such triple mutated antibodies are disclosed herein. Consequently, the triple mutated antibodies contain a modified effector function through Fc silencing and are capable of site-specific conjugation at L328C to form an antibody-drug-conjugate (ADC) which can be administered to patients and provide a method of treating cancer, immunological and neurological disorders.

Abstract: Borylated Amino Acid (“BAA”) compositions and methods of making BAAs are disclosed herein. Consequently, the BAAs can be administered to patients as a Neutron Capture Agent and provide a method of treating cancer, immunological disorders and other disease by utilizing a Neutron Capture Therapy modality.

Abstract: Borylated Amino Acid compositions comprising tyrosine derivatives BTS and BTS(OMe) and novel methods of making BTS and BTS(OMe) are disclosed herein. Consequently, the BTS and/or BTS(OMe) can be scaled up to commercial scale and administered to patients as a Neutron Capture Agent and provide a method of treating cancer, immunological disorders, and other disease by utilizing a Neutron Capture Therapy modality.

Abstract: Borylated Amino Acid (“BAA”) compositions and methods of making BAAs are disclosed herein. Consequently, the BAAs can be administered to patients as a Neutron Capture Agent and provide a method of treating cancer, immunological disorders and other disease by utilizing a Neutron Capture Therapy modality.

Abstract: Boron Enriched Linker (“BEL”) compositions and methods of making BELs are disclosed herein. Consequently, the BELs can be conjugated to antibodies or antibody fragments to create Antibody Boron Conjugates (“ABCs”) to provide a method of treating cancer, immunological disorders and other disease by utilizing a Neutron Capture Therapy modality.

Abstract: Biodegradable Periodic Mesoporous Organosilica (BPMO) nanomaterials and methods of making BPMOs loaded with Neutron Capture Agents are disclosed herein. Consequently, the BPMOs loaded with Neutron Capture Agents provide a method of treating cancer, immunological disorders and other disease by utilizing a Neutron Capture Therapy modality.